Literature DB >> 30642645

Clinical impact of cardiovascular magnetic resonance with optimized myocardial scar detection in patients with cardiac implantable devices.

Anish N Bhuva1, Peter Kellman2, Adam Graham3, Manish Ramlall4, Redha Boubertakh4, Patricia Feuchter4, Angela Hawkins3, Martin Lowe3, Pier D Lambiase5, Neha Sekhri4, Richard J Schilling3, James C Moon1, Charlotte H Manisty6.   

Abstract

BACKGROUND: Myocardial scar assessment using late gadolinium enhancement Cardiovascular Magnetic Resonance (LGE CMR) is commonly indicated for patients with cardiac implantable electronic devices (CIEDs), however metal artifact can degrade images. We evaluated the clinical impact of LGE CMR incorporating a device-dependent metal artifact reduction strategy in patients with CIEDs.
METHODS: 136 CMR studies were performed in 133 consecutive patients (age 56 ± 19 years, 69% male) with CIEDs (22% implantable loop recorders [ILRs], 40% permanent pacemakers [PPMs], 38% implantable cardioverter defibrillators [ICDs]; 42% non-MRI conditional) over 2 years, without complication. LGE imaging was tailored to the CIED, using a wideband sequence for left-sided PPMs and ICDs and conventional sequences for ILRs and right-sided PPMs, scoring segmental artifact. Diagnostic utility and impact on clinical management were scored by consensus of experts.
RESULTS: CMR provided unexpected diagnoses in 22 (16%) and changed management in 113 (83%) patients. Myocardial scar was present in 92 (68%), with other abnormalities detected in another 13%. Using conventional LGE, 43 (32%) studies were non-diagnostic (79% of defibrillators) compared to 0% using wideband LGE imaging. Wideband LGE results changed clinical management in an additional 39 (75%) defibrillator patients and 10 (19%) pacemaker patients when compared to imaging with conventional LGE sequences.
CONCLUSION: The clinical yield from CMR using optimized LGE sequences in patients with CIEDs is high with no demonstrated clinical risk. A device-dependent LGE imaging strategy using wideband LGE is needed to achieve clinical utility especially in ICD recipients.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Cardiovascular magnetic resonance; Defibrillator; Fibrosis; Late gadolinium enhancement; Pacemaker; Wideband

Mesh:

Year:  2019        PMID: 30642645     DOI: 10.1016/j.ijcard.2019.01.005

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  9 in total

Review 1.  Role of Cardiac MRI Imaging of Focal and Diffuse Inflammation and Fibrosis in Cardiomyopathy Patients Who Have Pacemakers/ICD Devices.

Authors:  Ananna Zaman; Samantha Zhao; Jordana Kron; Antonio Abbate; Anna Tomdio; W Gregory Hundley; Jennifer H Jordan
Journal:  Curr Cardiol Rep       Date:  2022-08-19       Impact factor: 3.955

2.  Impact of Wideband Late Gadolinium Enhancement Cardiac Magnetic Resonance Imaging on Device-Related Artifacts in Different Implantable Cardioverter-Defibrillator Types.

Authors:  Amita Singh; Wensu Chen; Hena N Patel; Nazia Alvi; Keigo Kawaji; Stephanie A Besser; Roderick Tung; Jiangang Zou; Roberto M Lang; Victor Mor-Avi; Amit R Patel
Journal:  J Magn Reson Imaging       Date:  2021-03-19       Impact factor: 4.813

Review 3.  The Added Value of Cardiac Magnetic Resonance in Muscular Dystrophies.

Authors:  Mariana M Lamacie; Jodi Warman-Chardon; Andrew M Crean; Anca Florian; Karim Wahbi
Journal:  J Neuromuscul Dis       Date:  2019

4.  Feasibility and validation of trans-valvular flow derived by four-dimensional flow cardiovascular magnetic resonance imaging in pacemaker recipients.

Authors:  Christopher E D Saunderson; Maria F Paton; Amrit Chowdhary; Louise A E Brown; John Gierula; Anshuman Sengupta; Christopher Kelly; Pei G Chew; Arka Das; Thomas P Craven; Rob J van der Geest; David M Higgins; Liang Zhong; Klaus K Witte; John P Greenwood; Sven Plein; Pankaj Garg; Peter P Swoboda
Journal:  Magn Reson Imaging       Date:  2020-09-02       Impact factor: 2.546

5.  Measurement of T1 Mapping in Patients With Cardiac Devices: Off-Resonance Error Extends Beyond Visual Artifact but Can Be Quantified and Corrected.

Authors:  Anish N Bhuva; Thomas A Treibel; Andreas Seraphim; Paul Scully; Kristopher D Knott; João B Augusto; Camilla Torlasco; Katia Menacho; Clement Lau; Kush Patel; James C Moon; Peter Kellman; Charlotte H Manisty
Journal:  Front Cardiovasc Med       Date:  2021-01-29

6.  Detrimental Immediate- and Medium-Term Clinical Effects of Right Ventricular Pacing in Patients With Myocardial Fibrosis.

Authors:  Christopher E D Saunderson; Maria F Paton; Louise A E Brown; John Gierula; Pei G Chew; Arka Das; Anshuman Sengupta; Thomas P Craven; Amrit Chowdhary; Aaron Koshy; Hazel White; Eylem Levelt; Erica Dall'Armellina; Pankaj Garg; Klaus K Witte; John P Greenwood; Sven Plein; Peter P Swoboda
Journal:  Circ Cardiovasc Imaging       Date:  2021-05-18       Impact factor: 7.792

Review 7.  Cardiac Magnetic Resonance for Ventricular Tachycardia Ablation and Risk Stratification.

Authors:  Ivo Roca-Luque; Lluis Mont-Girbau
Journal:  Front Cardiovasc Med       Date:  2022-01-12

8.  Evidence to support magnetic resonance conditional labelling of all pacemaker and defibrillator leads in patients with cardiac implantable electronic devices.

Authors:  Anish N Bhuva; Russell Moralee; Tamara Brunker; Karen Lascelles; Lizette Cash; Kush P Patel; Martin Lowe; Neha Sekhri; Francisco Alpendurada; Dudley J Pennell; Richard Schilling; Pier D Lambiase; Anthony Chow; James C Moon; Harold Litt; A John Baksi; Charlotte H Manisty
Journal:  Eur Heart J       Date:  2022-07-07       Impact factor: 35.855

9.  Clinical experience regarding safety and diagnostic value of cardiovascular magnetic resonance in patients with a subcutaneous implanted cardioverter/defibrillator (S-ICD) at 1.5 T.

Authors:  Viktoria Holtstiege; Claudia Meier; Michael Bietenbeck; Grigorios Chatzantonis; Anca Florian; Julia Köbe; Florian Reinke; Lars Eckardt; Ali Yilmaz
Journal:  J Cardiovasc Magn Reson       Date:  2020-05-18       Impact factor: 5.364

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.